Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2010 Filed Jun 2, 2010 19:27 UTC |
CORDES EUGENEDirector
|
GrantStock Option · Derivative | 20,000 | $0.00 Strike: $34.24 | $0.00 |
DisclosureSEC source: 0000875320-10-000028 · edgar.xml · derivative · entry 1 CORDES EUGENE · CIK 0001192609 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2020-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2010 Filed Jun 2, 2010 19:28 UTC |
BOGER JOSHUA SDirector
|
GrantStock Option · Derivative | 20,000 | $0.00 Strike: $34.24 | $0.00 |
DisclosureSEC source: 0000875320-10-000029 · edgar.xml · derivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2020-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2010 Filed Jun 2, 2010 19:30 UTC |
SACHS BRUCE IDirector
|
GrantStock Option · Derivative | 20,000 | $0.00 Strike: $34.24 | $0.00 |
DisclosureSEC source: 0000875320-10-000030 · edgar.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2020-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2010 Filed Jun 2, 2010 19:31 UTC |
COLLINSON STUART JDirector
|
GrantStock Option · Derivative | 20,000 | $0.00 Strike: $34.24 | $0.00 |
DisclosureSEC source: 0000875320-10-000031 · edgar.xml · derivative · entry 1 COLLINSON STUART J · CIK 0001197037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2020-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2010 Filed Jun 2, 2010 19:33 UTC |
WINGER DENNIS LDirector
|
GrantStock Option · Derivative | 20,000 | $0.00 Strike: $34.24 | $0.00 |
DisclosureSEC source: 0000875320-10-000032 · edgar.xml · derivative · entry 1 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2020-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2010 Filed Jun 2, 2010 19:34 UTC |
LEIDEN JEFFREY MDirector
|
GrantStock Option · Derivative | 20,000 | $0.00 Strike: $34.24 | $0.00 |
DisclosureSEC source: 0000875320-10-000033 · edgar.xml · derivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2020-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| May 18, 2010 Filed May 19, 2010 19:35 UTC |
Silva Paul MV.P. and Corporate Controller
|
SaleCommon Stock | 526 | $37.61 | $19,782.86 |
DisclosureSEC source: 0000875320-10-000024 · edgar.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · V.P. and Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,625 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a wieghted average price of $37.61 (range $37.27 to $38.00). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 18, 2010 Filed May 19, 2010 19:38 UTC |
SMITH IAN FEVP & CFO
|
SaleCommon Stock | 774 | $37.68 | $29,164.32 |
DisclosureSEC source: 0000875320-10-000025 · edgar.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,877 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $37.68 (range $37.45 to $37.97). F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 17, 2010 Filed May 18, 2010 19:16 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
Exercise / conversionStock Option · Derivative | 1,600 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0000875320-10-000023 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 1,600 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| May 17, 2010 Filed May 18, 2010 19:16 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
SaleCommon Stock | 1,600 | $37.39 | $59,824.00 |
DisclosureSEC source: 0000875320-10-000023 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,234 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $37.39 (range $36.87 to $37.87). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 17, 2010 Filed May 18, 2010 19:16 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
Exercise / conversionCommon Stock | 1,600 | $10.41 | $16,656.00 |
DisclosureSEC source: 0000875320-10-000023 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2010 Filed May 10, 2010 20:51 UTC |
SMITH IAN FEVP & CFO
|
SaleCommon Stock | 9,131 | $36.16 | $330,176.96 |
DisclosureSEC source: 0000875320-10-000021 · edgar.xml · nonDerivative · entry 2 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,877 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan established under Rule 10b5-1. F3 · price: Open market sales reported on this line occurred at a weighted average price of $36.16 (range $36.00 to $36.50). F4 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 07, 2010 Filed May 10, 2010 20:51 UTC |
SMITH IAN FEVP & CFO
|
SaleCommon Stock | 5,869 | $35.72 | $209,640.68 |
DisclosureSEC source: 0000875320-10-000021 · edgar.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,008 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $35.72 (range $35.06 to $35.99). F4 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 07, 2010 Filed May 10, 2010 20:53 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
SaleCommon Stock | 2,987 | $36.18 | $108,069.66 |
DisclosureSEC source: 0000875320-10-000022 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,234 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Open market sales reported on this line occurred at a weighted average price of $36.18 (range $36.02 to $36.44). F4 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 07, 2010 Filed May 10, 2010 20:53 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
SaleCommon Stock | 3,284 | $35.78 | $117,501.52 |
DisclosureSEC source: 0000875320-10-000022 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,221 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $35.78 (range $35.11 to $36.00). F4 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 04, 2010 Filed May 5, 2010 20:52 UTC |
LEIDEN JEFFREY MDirector
|
PurchaseCommon Stock | 1,300 | $38.40 | $49,920.00 |
DisclosureSEC source: 0000875320-10-000020 · edgar.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,600 Read SEC document |
| April 23, 2010 Filed Apr 26, 2010 14:07 UTC |
LEIDEN JEFFREY MDirector
|
PurchaseCommon Stock | 1,300 | $38.60 | $50,180.00 |
DisclosureSEC source: 0000875320-10-000019 · edgar.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 Read SEC document |
| April 15, 2010 Filed Apr 16, 2010 19:50 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
Exercise / conversionStock Option · Derivative | 1,600 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0000875320-10-000018 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 1,600 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| April 15, 2010 Filed Apr 16, 2010 19:50 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
SaleCommon Stock | 1,600 | $39.61 | $63,376.00 |
DisclosureSEC source: 0000875320-10-000018 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,505 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $39.61 (range $39.42 to $39.87). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| April 15, 2010 Filed Apr 16, 2010 19:50 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
Exercise / conversionCommon Stock | 1,600 | $10.41 | $16,656.00 |
DisclosureSEC source: 0000875320-10-000018 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 05, 2010 Filed Apr 6, 2010 18:37 UTC |
SMITH IAN FEVP & CFO
|
SaleCommon Stock | 18,242 | $40.75 | $743,361.50 |
DisclosureSEC source: 0000875320-10-000017 · edgar.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,877 F1 · kind: Transaction made pursuant to Mr. Smith's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $40.75 (range $40.61 to $41.04). F3 · price: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| March 15, 2010 Filed Mar 16, 2010 20:18 UTC |
BRIMBLECOMBE ROGER WDirector
|
Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $38.44 | $0.00 |
DisclosureSEC source: 0000875320-10-000015 · edgar.xml · derivative · entry 3 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2010-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Right to buy under under 1996 Stock and Option Plan, fully vested on grant date, 6/1/2000. Read SEC document |
| March 15, 2010 Filed Mar 16, 2010 20:18 UTC |
BRIMBLECOMBE ROGER WDirector
|
SaleCommon Stock | 10,000 | $43.10 | $431,000.00 |
DisclosureSEC source: 0000875320-10-000015 · edgar.xml · nonDerivative · entry 2 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to Dr. Brimblecombe's company approved sales plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $43.10 (range $42.80 to $43.52). F3 · price: Dr. Brimblecombe undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| March 15, 2010 Filed Mar 16, 2010 20:18 UTC |
BRIMBLECOMBE ROGER WDirector
|
Exercise / conversionCommon Stock | 10,000 | $38.44 | $384,400.00 |
DisclosureSEC source: 0000875320-10-000015 · edgar.xml · nonDerivative · entry 1 BRIMBLECOMBE ROGER W · CIK 0001197034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2010 Filed Mar 16, 2010 20:20 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
Exercise / conversionStock Option · Derivative | 1,600 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0000875320-10-000016 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,600 Underlying: Common Stock · 1,600 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| March 15, 2010 Filed Mar 16, 2010 20:20 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
SaleCommon Stock | 1,600 | $43.08 | $68,928.00 |
DisclosureSEC source: 0000875320-10-000016 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,505 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $43.08 (range $42.80 to $43.52). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| March 15, 2010 Filed Mar 16, 2010 20:20 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
Exercise / conversionCommon Stock | 1,600 | $10.41 | $16,656.00 |
DisclosureSEC source: 0000875320-10-000016 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 18:24 UTC |
WINGER DENNIS LDirector
|
PurchaseCommon Stock | 6,500 | $38.54 | $250,510.00 |
DisclosureSEC source: 0000875320-10-000013 · edgar.xml · nonDerivative · entry 1 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Self as Trustee for the Dennis L. Winger and Barbara L. Waldman Rev. Trust Disclosed balance after: 6,500 Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 18:28 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
Exercise / conversionStock Option · Derivative | 1,600 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0000875320-10-000014 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,120 Underlying: Common Stock · 1,600 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 18:28 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
SaleCommon Stock | 1,600 | $38.55 | $61,680.00 |
DisclosureSEC source: 0000875320-10-000014 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,505 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $38.55 (range $38.46 to $38.65). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 18:28 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
Exercise / conversionCommon Stock | 1,600 | $10.41 | $16,656.00 |
DisclosureSEC source: 0000875320-10-000014 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2010 Filed Feb 12, 2010 17:57 UTC |
CORDES EUGENEDirector
|
SaleCommon Stock | 645 | $38.53 | $24,851.85 |
DisclosureSEC source: 0000875320-10-000012 · edgar.xml · nonDerivative · entry 2 CORDES EUGENE · CIK 0001192609 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Read SEC document |
| February 11, 2010 Filed Feb 12, 2010 17:57 UTC |
CORDES EUGENEDirector
|
SaleCommon Stock | 1,355 | $38.52 | $52,194.60 |
DisclosureSEC source: 0000875320-10-000012 · edgar.xml · nonDerivative · entry 1 CORDES EUGENE · CIK 0001192609 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,645 Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:36 UTC |
Kelly LisaSVP, Human Resources
|
GrantStock Option · Derivative | 76,250 | $0.00 Strike: $39.05 | $0.00 |
DisclosureSEC source: 0000875320-10-000005 · edgar.xml · derivative · entry 3 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,250 Underlying: Common Stock · 76,250 shares Expires 2020-02-03 F2 · shares: Stock option under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments over four years. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:36 UTC |
Kelly LisaSVP, Human Resources
|
GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0000875320-10-000005 · edgar.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,563 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/4/2014, subject to 50% acceleration upon receiving U.S. marketing approval for telaprevir; and to 50% acceleration upon either (a) reaching specified telaprevir sales levels during 18 months following its U.S. launch or (b) launch of any additional drug beyond telaprevir prior to December 31, 2012. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:39 UTC |
SMITH IAN FEVP & CFO
|
GrantStock Options · Derivative | 90,625 | $0.00 Strike: $39.05 | $0.00 |
DisclosureSEC source: 0000875320-10-000006 · edgar.xml · derivative · entry 3 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,625 Underlying: Common Stock · 90,625 shares Expires 2020-02-03 F2 · shares: Stock option under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments over four years. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:39 UTC |
SMITH IAN FEVP & CFO
|
GrantCommon Stock | 12,084 | $0.01 | $120.84 |
DisclosureSEC source: 0000875320-10-000006 · edgar.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,119 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/4/2014, subject to 50% acceleration upon receiving U.S. marketing approval for telaprevir; and to 50% acceleration upon either (a) reaching specified telaprevir sales levels during 18 months following its U.S. launch or (b) launch of any additional drug beyond telaprevir prior to December 31, 2012. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:43 UTC |
BOGER KENNETH SSVP & General Counsel
|
GrantStock Option · Derivative | 76,250 | $0.00 Strike: $39.05 | $0.00 |
DisclosureSEC source: 0000875320-10-000008 · edgar.xml · derivative · entry 3 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,250 Underlying: Common Stock · 76,250 shares Expires 2020-02-03 F2 · shares: Stock option under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments over four years. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:43 UTC |
BOGER KENNETH SSVP & General Counsel
|
GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0000875320-10-000008 · edgar.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,023 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/4/2014, subject to 50% acceleration upon receiving U.S. marketing approval for telaprevir; and to 50% acceleration upon either (a) reaching specified telaprevir sales levels during 18 months following its U.S. launch or (b) launch of any additional drug beyond telaprevir prior to December 31, 2012. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:40 UTC |
MUELLER PETERDirector · EVP, Global R&D, CSO
|
GrantStock Option · Derivative | 108,750 | $0.00 Strike: $39.05 | $0.00 |
DisclosureSEC source: 0000875320-10-000007 · edgar.xml · derivative · entry 3 MUELLER PETER · CIK 0001256126 · Director · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,750 Underlying: Common Stock · 108,750 shares Expires 2020-02-03 F2 · shares: Stock option under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments over four years. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:40 UTC |
MUELLER PETERDirector · EVP, Global R&D, CSO
|
GrantCommon Stock | 14,501 | $0.01 | $145.01 |
DisclosureSEC source: 0000875320-10-000007 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · Director · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,505 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/4/2014, subject to 50% acceleration upon receiving U.S. marketing approval for telaprevir; and to 50% acceleration upon either (a) reaching specified telaprevir sales levels during 18 months following its U.S. launch or (b) launch of any additional drug beyond telaprevir prior to December 31, 2012. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:45 UTC |
Emmens MatthewDirector · President & CEO
|
GrantStock Options · Derivative | 354,000 | $0.00 Strike: $39.05 | $0.00 |
DisclosureSEC source: 0000875320-10-000009 · edgar.xml · derivative · entry 2 Emmens Matthew · CIK 0001298332 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,000 Underlying: Common Stock · 354,000 shares Expires 2020-02-03 F2 · shares: Stock option under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments over four years. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:45 UTC |
Emmens MatthewDirector · President & CEO
|
GrantCommon Stock | 47,201 | $0.01 | $472.01 |
DisclosureSEC source: 0000875320-10-000009 · edgar.xml · nonDerivative · entry 1 Emmens Matthew · CIK 0001298332 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,205 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/4/2014, subject to 50% acceleration upon receiving U.S. marketing approval for telaprevir; and to 50% acceleration upon either (a) reaching specified telaprevir sales levels during 18 months following its U.S. launch or (b) launch of any additional drug beyond telaprevir prior to December 31, 2012. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:48 UTC |
Silva Paul MV.P. and Corporate Controller
|
GrantStock Option · Derivative | 22,500 | $0.00 Strike: $39.05 | $0.00 |
DisclosureSEC source: 0000875320-10-000010 · edgar.xml · derivative · entry 3 Silva Paul M · CIK 0001446372 · V.P. and Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2020-02-03 F2 · shares: Stock option under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments over four years. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:48 UTC |
Silva Paul MV.P. and Corporate Controller
|
GrantCommon Stock | 3,000 | $0.01 | $30.00 |
DisclosureSEC source: 0000875320-10-000010 · edgar.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · V.P. and Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,625 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/4/2014, subject to 50% acceleration upon receiving U.S. marketing approval for telaprevir; and to 50% acceleration upon either (a) reaching specified telaprevir sales levels during 18 months following its U.S. launch or (b) launch of any additional drug beyond telaprevir prior to December 31, 2012. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:50 UTC |
Sachdev AmitSVP, Corp Affairs & Pub Policy
|
GrantStock Option · Derivative | 76,250 | $0.00 Strike: $39.05 | $0.00 |
DisclosureSEC source: 0000875320-10-000011 · edgar.xml · derivative · entry 3 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,250 Underlying: Common Stock · 76,250 shares Expires 2020-02-03 F2 · shares: Stock option under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments over four years. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:50 UTC |
Sachdev AmitSVP, Corp Affairs & Pub Policy
|
GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0000875320-10-000011 · edgar.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,983 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/4/2014, subject to 50% acceleration upon receiving U.S. marketing approval for telaprevir; and to 50% acceleration upon either (a) reaching specified telaprevir sales levels during 18 months following its U.S. launch or (b) launch of any additional drug beyond telaprevir prior to December 31, 2012. Read SEC document |
| February 03, 2010 Filed Feb 4, 2010 20:12 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
SaleCommon Stock | 3,844 | $40.07 | $154,029.08 |
DisclosureSEC source: 0000875320-10-000004 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,004 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan establishded under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $40.07 (range $40.02 to $40.23). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 26, 2010 Filed Jan 27, 2010 22:03 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
SaleCommon Stock | 2,026 | $39.39 | $79,804.14 |
DisclosureSEC source: 0000875320-10-000002 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,848 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan establishded under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $39.39 (range $39.15 to $39.62). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 26, 2010 Filed Jan 27, 2010 22:05 UTC |
Kelly LisaSVP, Human Resources
|
SaleCommon Stock | 583 | $39.48 | $23,016.84 |
DisclosureSEC source: 0000875320-10-000003 · edgar.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,397 F1 · kind: Transaction made pursuant to Ms. Kelly's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $39.48 (range $39.14 to $39.63). F3 · price: Ms. Kelly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.